Evolution of advanced technologies in prostate cancer radiotherapy

Nature Reviews Urology

Volumn 10, Issue 10, 2013, Pages 565-579

  Zaorsky, Nicholas G ^a   Harrison, Amy S ^b   Trabulsi, Edouard J ^b   Gomella, Leonard G ^b   Showalter, Timothy N ^c   Hurwitz, Mark D ^b   Dicker, Adam P ^b   Den, Robert B ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; IMAGE GUIDED RADIOTHERAPY; IMAGING SYSTEM; INTENSITY MODULATED RADIATION THERAPY; LAPAROTOMY; MULTILEAF COLLIMATOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOTHERAPY EQUIPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84885587059     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.185     Document Type: Review

References (153)

1. Center, M. M. et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 61, 1079-1092 (2012).
2. Cahlon, O. et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 71, 330-337 (2008).
3. Budiharto, T., Haustermans, K. & Kovacs, G. External beam radiotherapy for prostate cancer. J. Endourol. 24, 781-789 (2010).
4. Kao, J., Cesaretti, J. A., Stone, N. N. & Stock, R. G. Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity. Curr. Urol. Rep. 12, 237-242 (2011).
5. Button, M. R. & Staffurth, J. N. Clinical application of image-guided radiotherapy in bladder and prostate cancer. Clin. Oncol. (R. Coll. Radiol.) 22, 698-706 (2010).
6. Stephans, K. L., Xia, P., Tendulkar, R. D. & Ciezki, J. P. The current status of image-guided external beam radiotherapy for prostate cancer. Curr. Opin. Urol. 20, 223-228 (2010).
7. van Herk, M. Different styles of image-guided radiotherapy. Semin. Radiat. Oncol. 17, 258-267 (2007).
8. Hartford, A. C. et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int. J. Radiat. Oncol. Biol. Phys. 73, 9-14 (2009).
9. Hummel, S., Simpson, E. L., Hemingway, P., Stevenson, M. D. & Rees, A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol. Assess. 14, 1-108, iii-iv (2010).
10. Bauman, G., Rumble, R. B., Chen, J., Loblaw, A. & Warde, P. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin. Oncol. (R. Coll. Radiol.) 24, 461-473 (2012).
11. Fowler, J., Chappell, R. & Ritter, M. Is a/ß for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys. 50, 1021-1031 (2001).
12. Mohler, J. L. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J. Natl Compr. Canc. Netw. 8, 145 (2010).
13. Zaorsky, N. G., Trabulsi, E. J., Lin, J. & Den, R. B. Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin. Oncol. 40, 308-321 (2013).
14. Grimm, P. et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 109 (Suppl. 1), 22-29 (2012).
15. Dandapani, S. V. & Sanda, M. G. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin. Radiat. Oncol. 18, 67-72 (2008).
16. Graf, R., Boehmer, D., Budach, V. & Wust, P. Interfraction rotation of the prostate as evaluated by kilovoltage X-ray fiducial marker imaging in intensity-modulated radiotherapy of localized prostate cancer. Med. Dosim. 37, 396-400 (2012).
17. Owen, R. et al. Interfraction prostate rotation determined from in-room computerized tomography images. Med. Dosim. 36, 188-194 (2011).
18. Li, J. S. et al. Gains from real-time tracking of prostate motion during external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 75, 1613-1620 (2009).
19. Litzenberg, D. W. et al. Prostate intrafraction translation margins for real-time monitoring and correction strategies. Prostate Cancer 2012, 130579 (2012).
20. Amro, H. et al. The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 85, 230-236 (2012).
21. Peng, C. et al. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 79, 909-914 (2011).
22. Zelefsky, M. J. et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 125-129 (2012).
23. Heemsbergen, W. D. et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 67, 1418-1424 (2007).
24. de Crevoisier, R. et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 965-973 (2005).
25. Song, W. Y., Schaly, B., Bauman, G., Battista, J. J. & Van Dyk, J. Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: a radiobiologic analysis. Int. J. Radiat. Oncol. Biol. Phys. 64, 289-300 (2006).
26. Ost, P. et al. A comparison of the acute toxicity profile between two-dimensional and three-dimensional image-guided radiotherapy for postoperative prostate cancer. Clin. Oncol. (R. Coll. Radiol.) 23, 344-349 (2011).
27. Albert, J. M. et al. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy 12, 30-37 (2013).
28. Hanks, G. E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr. 7, 75-84 (1988).
29. Kuban, D. A. et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 67-74 (2008).
30. Al-Mamgani, A. et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, 980-988 (2008).
31. Zietman, A. L. et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233-1239 (2005).
32. Zietman, A. L. et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therpay in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J. Clin. Oncol. 28, 1106-1111 (2010).
33. Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475-487 (2007).
34. Yoshimura, K. et al. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy. Prostate Cancer Prostatic Dis. 10, 288-292 (2007).
35. Namiki, S. et al. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer. Jpn J. Clin. Oncol. 39, 732-738 (2009).
36. Galalae, R. M. et al. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer. Strahlenther. Onkol. 180, 582-589 (2004).
37. Kleinmann, N. et al. The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nat. Rev. Urol. 9, 258-265 (2012).
38. Sheets, N. C. et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307, 1611-1620 (2012).
39. Bekelman, J. E. et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, e325-e334 (2011).
40. Gray, P. J. et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119, 1729-1735 (2013).
41. Fowler, J. F., Ritter, M. A., Chappell, R. J. & Brenner, D. J. What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56, 1093-1104 (2003).
42. Brenner, D. J. et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low a/ß ratio), similar to late-responding normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 52, 6-13 (2002).
43. Park, C., Papiez, L., Zhang, S., Story, M. & Timmerman, R. D. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70, 847-852 (2008).
44. Tree, A. C., Alexander, E. J., Van As, N. J., Dearnaley, D. P. & Khoo, V. Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done? Clin. Oncol. (R. Coll. Radiol.) 25, 483-498 (2013).
45. Viani, G. A., Stefano, E. J. & Afonso, S. L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int. J. Radiat. Oncol. Biol. Phys. 74, 1405-1418 (2009).
46. Zelefsky, M. J. et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur. Urol. 60, 1133-1139 (2011).
47. Martinez, A. A. et al. Dose escalation improves cancer-related events at 10 years for intermediate-and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 79, 363-370 (2011).
48. Heysek, R. V. Modern brachytherapy for treatment of prostate cancer. Cancer Control 14, 238-243 (2007).
49. Glasgow, G. P., Bourland, J. D., Grigsby, P. W., Meli, J. A. & Weaver, K. A. Remote Afterloading Technology 1-29 (American Association of Physicists in Medicine, 1993).
50. Yamada, Y. et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11, 20-32 (2012).
51. Knaup, C. et al. Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med. Phys. 39, 3291-3298 (2012).
52. Yoshioka, Y. Current status and perspectives of brachytherapy for prostate cancer. Int. J. Clin. Oncol. 14, 31-36 (2009).
53. Zaorsky, N. G., Doyle, L. A., Hurwitz, M. D., Dicker, A. P. & Den, R. B. Do theoretical potential and advanced technology justify the use of high dose rate brachytherapy as monotherapy for prostate cancer? Expert Rev. Anticancer Ther. (in press).
54. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D. & Altieri, G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int. J. Radiat. Oncol. Biol. Phys. 61, 1306-1316 (2005).
55. Hoskin, P. J. et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother. Oncol. 103, 217-222 (2012).
56. Duchesne, G. M., Williams, S. G., Das, R. & Tai, K. H. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. Radiother. Oncol. 84, 128-134 (2007).
57. Demanes, D. J., Brandt, D., Schour, L. & Hill, D. R. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am. J. Clin. Oncol. 32, 342-347 (2009).
58. Kalkner, K. M. et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol. 46, 909-917 (2007).
59. Galalae, R. M. et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther. Onkol. 182, 135-141 (2006).
60. Demanes, D. J. et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, 1286-1292 (2011).
61. Tang, J. I., Williams, S. G., Tai, K. H., Dean, J. & Duchesne, G. M. A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: evidence of hypofractionation efficacy? Brachytherapy 5, 256-261 (2006).
62. Vargas, C. E. et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int. J. Radiat. Oncol. Biol. Phys. 66, 416-423 (2006).
63. Martinez, A. et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J. Urol. 169, 974-979; discussion 979-980 (2003).
64. Martinez, A. A. et al. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am. J. Clin. Oncol. 33, 481-488 (2010).
65. Yamoah, K., Stone, N. & Stock, R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 117, 5589-5600 (2011).
66. Myers, M. A. et al. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate. Brachytherapy 11, 292-298 (2012).
67. Zwahlen, D. R. et al. The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 83, 1655-1660 (2012).
68. Klayton, T. et al. Prostate bed motion during intensity-modulated radiotherapy treatment. Int. J. Radiat. Oncol. Biol. Phys. 84, 130-136 (2012).
69. Zaorsky, N. G., Ohri, N., Showalter, T. N., Dicker, A. P. & Den, R. B. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat. Rev. 9, 728-736 (2013).
70. Oliveira, S. M., Teixeira, N. J. & Fernandes, L. What do we know about the a/ß for prostate cancer? Med. Phys. 39, 3189-3201 (2012).
71. Lee, W. R. Extreme hypofractionation for prostate cancer. Expert Rev. Anticancer Ther. 9, 61-65 (2009).
72. Zaorsky, N. G., Studenski, M. T., Dicker, A. P., Gomella, L. & Den, R. B. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat. Rev. 39, 212-218 (2013).
73. McBride, S. M. et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118, 3681-3690 (2012).
74. Madsen, B. L. et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67, 1099-1105 (2007).
75. Katz, A. J., Santoro, M., DiBlasio, F. & Ashley, R. Stereotactic body radiation therapy for low, intermediate, and high-risk prostate cancer: disease control and quality of life. Int. J. Radiat. Oncol. 81, S100-S100 (2011).
76. Katz, A. J., Santoro, M., Ashley, R., Diblasio, F. & Witten, M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol. Cancer Res. Treat. 9, 575-582 (2010).
77. King, C. R., Brooks, J. D., Gill, H. & Presti, J. C. Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, 877-882 (2012).
78. Mantz, C. A., Fernandez, E., Zucker, I. & Harrison, S. A Phase II trial of real-time target tracking SBRT for low-risk prostate cancer utilizing the Calypso 4D localization system: patient-reported quality of life and toxicity outcomes [abstract 199]. Int. J. Radiat. Oncol. Biol. Phys. 81 (Suppl.), S100 (2011).
79. Boike, T. P. et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J. Clin. Oncol. 29, 2020-2026 (2011).
80. Tang, C. I. et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin. Oncol. (R. Coll. Radiol.) 20, 729-737 (2008).
81. Quon, H. et al. Phase II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localized prostate cancer: Toxicity results of pHART3 [abstract 48]. ASCO 2010 Genitourinary Cancers Symposium (San Francisco, CA, 2010).
82. Ritter, M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin. Radiat. Oncol. 18, 249-256 (2008).
83. Wennberg, B. & Lax, I. The impact of fractionation in SBRT: analysis with the linear quadratic model and the universal survival curve model. Acta Oncol. 52, 902-909 (2013).
84. Hossain, S. et al. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med. Phys. 35, 4041-4048 (2008).
85. Wilson, R. R. Radiological use of fast protons. Radiology 47, 487-491 (1946).
86. Coen, J. J. et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, e201-e209 (2012).
87. Shipley, W. U. et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int. J. Radiat. Oncol. 32, 3-12 (1995).
88. Mendenhall, N. P. et al. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82, 213-221 (2012).
89. Yonemoto, L. T. et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study. Int. J. Radiat. Oncol. Biol. Phys. 37, 21-29 (1997).
90. Kim, S. et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur. Urol. 60, 908-916 (2011).
91. Forman, J. D. & Porter, A. T. The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate. Semin. Urol. Oncol. 15, 239-243 (1997).
92. Laramore, G. E. et al. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. Am. J. Clin. Oncol. 16, 164-167 (1993).
93. Akakura, K. et al. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58, 252-258 (2004).
94. Tsuji, H. et al. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 63, 1153-1160 (2005).
95. Ishikawa, H. et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother. Oncol. 81, 57-64 (2006).
96. Ishikawa, H. et al. Carbon-ion radiation therapy for prostate cancer. Int. J. Urol. 19, 296-305 (2012).
97. Efstathiou, J. A., Gray, P. J. & Zietman, A. L. Proton beam therapy and localised prostate cancer: current status and controversies. Br. J. Cancer 108, 1225-1230 (2013).
98. MacDonald, S. M. et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int. J. Radiat. Oncol. Biol. Phys. 71, 979-986 (2008).
99. Childs, S. K. et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int. J. Radiat. Oncol. Biol. Phys. 82, 635-642 (2012).
100. Miralbell, R., Lomax, A., Cella, L. & Schneider, U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int. J. Radiat. Oncol. Biol. Phys. 54, 824-829 (2002).
101. Shah, A., Paly, J. J., Efstathiou, J. A. & Bekelman, J. E. Physician evaluation of internet health information on proton therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, e173-e177 (2013).
102. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01617161 (2013).
103. Zietman, A., Goitein, M. & Tepper, J. E. Technology evolution: is it survival of the fittest? J. Clin. Oncol. 28, 4275-4279 (2010).
104. Lawrence, T. S. & Feng, M. Protons for prostate cancer: the dream versus the reality. J. Natl Cancer Inst. 105, 7-8 (2013).
105. Widesott, L. et al. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int. J. Radiat. Oncol. Biol. Phys. 80, 1589-1600 (2011).
106. Schwarz, M. et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison. Radiother. Oncol. 98, 74-80 (2011).
107. Concato, J. et al. Observational methods in comparative effectiveness research. Am. J. Med. 123, e16-e23 (2010).
108. Epstein, R. S. & Teagarden, J. R. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28, 905-913 (2010).
109. Jagsi, R. et al. A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. Int. J. Radiat. Oncol. Biol. Phys. 84, 318-322 (2012).
110. Bekelman, J. E. & Hahn, S. M. The body of evidence for advanced technology in radiation oncology. J. Natl Cancer Inst. 105, 6-7 (2013).
111. Edge, S. B. et al. (eds) AJCC Cancer Staging Manual, 7th edn 457-468 (Springer, 2010).
112. Zaorsky, N. G., Li, T., Devarajan, K., Horwitz, E. M. & Buyyounouski, M. K. Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method. Cancer 118, 5535-5543 (2012).
113. Shen, X. et al. Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncol. 8, 37-54 (2012).
114. Zumsteg, Z. S. et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur. Urol. http://dx.doi.org/10. 1016/j.eururo.2013.03.033.
115. Butler, W. M., Morris, M. N., Merrick, G. S., Kurko, B. S. & Murray, B. C. Effect of body mass index on intrafraction prostate displacement monitored by real-time electromagnetic tracking. Int. J. Radiat. Oncol. Biol. Phys. 84, e173-e179 (2012).
116. de Crevoisier, R. et al. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 1529-1536 (2007).
117. Wang, B., Tward, J. D. & Salter, B. J. An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system. Med. Phys. 39, 4807-4811 (2012).
118. Pinkawa, M., Eble, M. J. & Mottaghy, F. M. PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev. Anticancer Ther. 11, 1033-1039 (2011).
119. Bouchelouche, K. et al. PET/CT Imaging and radioimmunotherapy of prostate cancer. Semin. Nucl. Med. 41, 29-44 (2011).
120. Seitz, M. et al. Functional magnetic resonance imaging in prostate cancer. Eur. Urol. 55, 801-814 (2009).
121. Sciarra, A. et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur. Urol. 59, 962-977 (2011).
122. Lips, I. M. et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials 12, 255 (2011).
123. Engels, B., Soete, G., Verellen, D. & Storme, G. Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int. J. Radiat. Oncol. Biol. Phys. 74, 388-391 (2009).
124. Song, D. Y. et al. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int. J. Radiat. Oncol. Biol. Phys. 87, 81-87 (2013).
125. Pinkawa, M. et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother. Oncol. 100, 436-441 (2011).
126. Noel, C. E., Santanam, L., Olsen, J. R., Baker, K. W. & Parikh, P. J. An automated method for adaptive radiation therapy for prostate cancer patients using continuous fiducial-based tracking. Phys. Med. Biol. 55, 65-82 (2010).
127. Mohan, R. et al. Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes. Int. J. Radiat. Oncol. Biol. Phys. 61, 1258-1266 (2005).
128. Thomsen, J. B., Arp, D. T. & Carl, J. Urethra sparing-potential of combined nickel-titanium stent and intensity modulated radiation therapy in prostate cancer. Radiother. Oncol. 103, 256-260 (2012).
129. Fellin, F. et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison. Radiother. Oncol. 107, 207-212 (2013).
130. Fachal, L. et al. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients. Radiother. Oncol. 105, 321-328 (2012).
131. Fachal, L. et al. TGFß1 SNPs and radio-induced toxicity in prostate cancer patients. Radiother. Oncol. 103, 206-209 (2012).
132. Goh, C. L. et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J. Intern. Med. 271, 353-365 (2012).
133. West, C. et al. Establishment of a radiogenomics consortium. Int. J. Radiat. Oncol. Biol. Phys. 76, 1295-1296 (2010).
134. Kerns, S. L. et al. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother. Oncol. 107, 372-376 (2013).
135. Peeters, S. T. et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 61, 1019-1034 (2005).
136. Yeoh, E. K. et al. Disturbed colonic motility contributes to anorectal symptoms and dysfunction after radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 78, 773-780 (2010).
137. Fonteyne, V., Lumen, N., Villeirs, G., Ost, P. & De Meerleer, G. Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. Adv. Urol. 2012, 368528 (2012).
138. Fonteyne, V., De Neve, W., Villeirs, G., De Wagter, C. & De Meerleer, G. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother. Oncol. 84, 156-163 (2007).
139. Denham, J. W. et al. Is there more than one late radiation proctitis syndrome? Radiother. Oncol. 51, 43-53 (1999).
140. Potters, L. et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 326-332 (2010).
141. Yeoh, E. K. et al. Pathophysiology and natural history of anorectal sequelae following radiation therapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 84, e593-e599 (2012).
142. Vordermark, D. et al. Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: importance of baseline symptoms and of prostate-V150. Radiother. Oncol. 91, 217-224 (2009).
143. Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177, 2106-2131 (2007).
144. Haynes, B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 319, 652-653 (1999).
145. Popiolek, M. et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur. Urol. 63, 428-435 (2013).
146. Johansson, J. E. et al. Natural history of early, localized prostate cancer. JAMA 291, 2713-2719 (2004).
147. Konski, A. Cost, quality, and value in healthcare: a new paradigm. Oncology (Willston Park) 24, 542-543 (2010).
148. Perez, C. A. et al. Cost accounting in radiation oncology: a computer-based model for reimbursement. Int. J. Radiat. Oncol. Biol. Phys. 25, 895-906 (1993).
149. Lievens, Y., van den Bogaert, W. & Kesteloot, K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57, 522-535 (2003).
150. Norlund, A. Costs of radiotherapy. Acta Oncol. 42, 411-415 (2003).
151. Kesteloot, K., Lievens, Y. & van der Schueren, E. Improved management of radiotherapy departments through accurate cost data. Radiother. Oncol. 55, 251-262 (2000).
152. Van de Werf, E., Lievens, Y., Verstraete, J., Pauwels, K. & Van den Bogaert, W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother. Oncol. 93, 137-140 (2009).
153. Shah, C. et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 11, 441-445 (2012).